(1−3) Limitations of small molecule drugs like ... activate protein–protein interactions provides another venue for developing peptide therapeutics. Peptidomimetics and chemical modifications of the ...

The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy, but risk is elevated in the first year of treatment, according to a ...

Telomerase is a reverse transcriptase enzyme complex capable of adding DNA sequence repeats (TTAGGG ... The mammalian target of rapamycin complex 1 (MTORC1) is a key protein in macroautophagy that is ...

Attribution (BY): Credit must be given to the creator. Lipidated analogues of glucagon-like peptide 1 (GLP-1) have gained enormous attention as long-acting peptide therapeutics for type 2 diabetes and ...

Background: Despite their potential, Glucagon-like peptide-1 receptor agonists (GLP-1 RA) have not been well studied in cardiac amyloidosis (CA) as randomized trials on GLP-1 RA have excluded patients ...

Share on Pinterest A new study compares the risks and benefits of using GLP-1 medications. Iuliia Burmistrova/Getty Images The use of glucagon-like peptide-1 receptor agonists (GLP-1 agonists ...

Changes to the intermediate filament (IF) protein, vimentin, were found to promote tumor growth by increasing cancer stemness in an oestrogen independent manner. Targeting vimentin and/or the long ...

Avacta is stepping up development of its peptide-drug conjugate (PDC), kicking off expansion cohorts in multiple tumor types after seeing one partial response in 10 salivary gland cancer patients.

Nine of these are essential–meaning your body needs them but can’t make them on its own, so you need to get them in your diet (1, 2). Not only is protein ... certain amino acids, like leucine ...